What just happened?
Johnson & Johnson Announces Strategic Agreement with Pacira BioSciences to Expand Early Intervention Offering for Osteoarthritis of the Knee Agreement enhances the Early Intervention portfolio to tackle the increasing burden of osteoarthritis through non-surgical solutions.
Tiger's Take: There will be a postponement for some TKRs, but not a TKR tsunami.
ZILRETTA will likely delay TKRs for a meaningful subset of US patients—think moderate OA folks gaining 6-18 months of mobility per cycle, reducing short-term surgery rates by 5-15% in treated cohorts.
The J&J tie-...
